Ondansetron orally disintegrating tablets
    6.
    发明授权
    Ondansetron orally disintegrating tablets 失效
    昂丹司琼口服崩解片

    公开(公告)号:US07390503B1

    公开(公告)日:2008-06-24

    申请号:US10923021

    申请日:2004-08-23

    IPC分类号: A61K9/20 A61K9/14 A61K9/50

    摘要: An ondansetron solid orally disintegrating dosage form for oral administration having at least one first water-dispersible component or water-insoluble cellulose derivative, a component having a —CHOH functional group, a disintegrating agent and at least one lubricant is provided. The dosage form can comprise ondansetron, a hydrophilic polymer such as microcrystalline cellulose, a component having a —CHOH functional group such as mannitol or xylitol and a disintegrating agent such as crospovidone. The lubricant may be a mixture of magnesium stearate, sodium stearyl fumarate and colloidal silicon dioxide. The present invention provides a non-effervescent tablet comprising the ondansetron dosage form. Another aspect of the invention is the treatment of emesis such as nausea and vomiting caused by cancer chemotherapy and radiation by the administration of the ondansetron formulation of the present composition. Finally, a process of forming an ondansetron disintegrating tablet using the ondansetron dosage form is disclosed.

    摘要翻译: 提供了具有至少一种第一水分散性成分或水不溶性纤维素衍生物,具有-CHOH官能团的成分,崩解剂和至少一种润滑剂的口服的昂丹司琼固体口腔崩解剂型。 剂型可以包含昂丹司琼,亲水性聚合物如微晶纤维素,具有-CHOH官能团的组分如甘露醇或木糖醇和崩解剂如交聚维酮。 润滑剂可以是硬脂酸镁,硬脂酰富马酸钠和胶体二氧化硅的混合物。 本发明提供了包含昂丹司琼剂型的非泡腾片剂。 本发明的另一方面是通过施用本发明组合物的昂丹司琼制剂来治疗呕吐,例如由癌症化疗和放射引起的恶心和呕吐。 最后,公开了使用昂丹司琼剂型形成昂丹司琼崩解片的方法。

    Combination pharmaceutical composition and associated methods
    10.
    发明授权
    Combination pharmaceutical composition and associated methods 失效
    组合药物组合物及相关方法

    公开(公告)号:US06221390B1

    公开(公告)日:2001-04-24

    申请号:US08920219

    申请日:1997-08-25

    IPC分类号: A61K964

    摘要: A novel pharmaceutical combination is described, together with a method of making the same and a method of treating hypertensive patients using the same, wherein (1) the pharmaceutically active antihypertensive agent and citric acid and (2) the pharmaceutically active antikaliuretic agent and a nonionic surfactant are mixed, either together or separately, to form an essentially homogenous combination composition, and only thereafter blending with excipients to form the novel combination composition in solid dosage form.

    摘要翻译: 本发明描述了一种新型药物组合及其制备方法以及使用其的治疗高血压患者的方法,其中(1)药学活性抗高血压药和柠檬酸和(2)药用活性抗利尿剂和非离子表面活性剂 将表面活性剂一起或分开混合以形成基本均匀的组合组合物,然后仅与赋形剂混合以形成固体剂型的新型组合组合物。